Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan

Emerging Infectious Diseases

Volumn 16, Issue 6, 2010, Pages 926-935

  Ujike, Makoto ^a   Shimabukuro, Kozue ^a   Mochizuki, Kiku ^a   Obuchi, Masatsugu ^a   Kageyama, Tsutomu ^a   Shirakura, Masayuki ^a   Kishida, Noriko ^a   Yamashita, Kazuyo ^a   Horikawa, Hiroshi ^b   Kato, Yumiko ^b   Fujita, Nobuyuki ^b   Tashiro, Masato ^a   Odagiri, Takato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b NATIONAL INSTITUTE OF TECHNOLOGY AND EVALUATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; GENETIC ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEMAGGLUTINATION INHIBITION TEST; IC 50; INFLUENZA VIRUS A H1N1; JAPAN; NONHUMAN; SEQUENCE ANALYSIS;

AMANTADINE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; JAPAN; NEURAMINIDASE; OSELTAMIVIR; PHYLOGENY; SEASONS; SEQUENCE ANALYSIS, PROTEIN; TIME FACTORS; VIRAL MATRIX PROTEINS; ZANAMIVIR;

EID: 77952676324     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1606.091623     Document Type: Article

References (35)

1. Cauchemez S, Valleron AJ, Boëlle PY, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza transmission from sentinel data. Nature. 2008;452:750-4. DOI: 10.1038/nature06732
2. Fleming DM. Managing influenza: amantadine, rimantadine and beyond. Int J Clin Pract. 2001;55:189-95.
3. Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005-2006. N Engl J Med. 2007;356:312-3. DOI: 10.1056/NEJMc062989
4. Saito R, Suzuki Y, Li D, Zaraket H, Sato I, Masaki H, et al. Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006-2007 influenza season in Japan. J Infect Dis. 2008;197:630-2. DOI: 10.1086/525055
5. World Health Organization. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during 2003-2006 influenza seasons. Wkly Epidemiol Rec. 2007;82: 149-50.
6. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50:2395-402. DOI: 10.1128/AAC.01339-05
7. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47:2264-72. DOI: 10.1128/AAC.47.7.2264-2272.2003
8. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284-92. DOI: 10.1128/AAC.00555-08
9. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007-lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill. 2009;14. pii: 19112.
10. Tashiro M, McKimm-Breschkin JL, Saito T, Klimov A, Macken C, Zambon M, et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir Ther. 2009;14:751-61. DOI: 10.3851/IMP1194
11. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 2008;4:e1000103. DOI: 10.1371/journal. ppat.1000103
12. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, et al. European Influenza Surveillance Scheme. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007/08 season. Emerg Infect Dis. 2009;15:552-60. DOI: 10.3201/eid1504.081280
13. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008;13. pii: 8026.
14. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007/08. Emerg Infect Dis. 2009;15:155-62. DOI: 10.3201/eid1502.081031
15. World Health Organization. WHO/ECDC frequently asked questions for oseltamivir resistance. 2008 Feb 15 [cited 2009 Oct 20]. http://www.who.int/csr/disease/influenza/oseltamivir_faqs/en/index.html
16. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir. 2009 Mar 21 [cited 2009 Oct 20]. http://www.who.int/csr/disease/influenza/h1n1_table/en/index.html
17. World Health Organization. 2002. Manual on animal influenza diagnosis and surveillance, 2nd ed. [cited 2009 Oct 20]. http://www.wpro.who.int/NR/rdonlyres/EFD2B9A7-2265-4AD0-BC98-97937-B4FA83C/0/manualonanimalaidiagnosisandsurveillance.pdf
18. Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol. 2003;41:742-50. DOI: 10.1128/JCM.41.2.742-750.2003
19. Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, Dharan N, et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 2009;81:16-24. DOI: 10.1016/j. antiviral.2008.08.008
20. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301:1034-41. DOI: 10.1001/jama.2009.294
21. Tamura D, Mitamura K, Yamazaki M, Fujino M, Nirasawa M, Kimura K, et al. Oseltamivir-resistant influenza a viruses circulating in Japan. J Clin Microbiol. 2009;47:1424-7. DOI: 10.1128/JCM.02396-08
22. Kawakami C, Obuchi M, Saikusa M, Noguchi Y, Ujike M, Odagiri T, et al. Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama City, Japan, during the 2007-2008 influenza season. Jpn J Infect Dis. 2009;62:83-6.
23. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55:307-17. DOI: 10.1016/S0166-3542(02)00053-0
24. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002;54:79-88. DOI: 10.1016/S0166-3542(01)00215-7
25. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis. 2004;190:1627-30. DOI: 10.1086/424572
26. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002;54:99-111. DOI: 10.1016/S0166-3542(01)00214-5
27. Barr IG, Deng YM, Iannello P, Hurt AC, Komadina N. Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries. Antiviral Res. 2008;80:200-5. DOI: 10.1016/j.antiviral.2008.06.008
28. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol. 2009;83:10366-73. DOI: 10.1128/JVI.01200-09
29. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol. 2006;80:8787-95. DOI: 10.1128/JVI.00477-06
30. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197-201. DOI: 10.1126/science.1176225
31. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-15. DOI: 10.1056/NEJMoa0903810
32. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med. 2009;360:2616-25. DOI: 10.1056/NEJMoa0903812
33. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459:1122-5. DOI: 10.1038/nature08182
34. World Health Organization. Viruses resistant to oseltamivir (Tami-flu) identified. 2009 Jul 8 [cited 2009 Oct 20]. http://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_resistance_20090708/en/index.html
35. World Health Organization. Antiviral use and the risk of drug resistance. Pandemic (H1N1) 2009 briefing note 12 [cited 2009 Oct 20]. http://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_use_20090925/en/index.html